Safety and efficacy of a non-steroidal anti-androgen, based on results of a post marketing surveillance of nilutamide

Abstract

The use, tolerability and ef®cacy of the non-steroidal anti-androgen nilutamide (Anandron 1 ) in daily clinical practice was investigated in this 5-y project. In total 725 patients were recruited from 27 Dutch centres. The investigated population was very heterogeneous and different therapeutic options were reported. We may conclude that in general good results have been obtained, especially in ®rst line combination therapy combined with luteinising hormone releasing hormone (LHRH) agonists. Patients with a good performance status at inclusion seem to bene®t more from nilutamide combination therapy. Prostate Cancer and Prostatic Diseases (2001) 4, 112±117.